Published in J Med Chem on March 01, 1991
In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci U S A (1993) 2.16
Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev (1995) 1.49
Target repurposing for neglected diseases. Future Med Chem (2011) 1.48
In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob Agents Chemother (1993) 1.33
In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother (1992) 1.13
In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrob Agents Chemother (1993) 1.00
Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles. J Virol (1991) 1.00
Pyrrolinone-based peptidomimetics. "Let the enzyme or receptor be the judge". Acc Chem Res (2010) 0.94
Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A (1988) 10.77
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 10.13
Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature (1986) 7.06
Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol (1991) 7.01
Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A (1984) 6.45
Cloning of bovine GAP and its interaction with oncogenic ras p21. Nature (1988) 5.56
Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature (1989) 4.80
Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (1992) 4.75
cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A (1987) 4.61
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Electron microscopic study of a slime layer. J Bacteriol (1969) 3.88
Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol (1992) 3.85
Mutant ras-encoded proteins with altered nucleotide binding exert dominant biological effects. Proc Natl Acad Sci U S A (1986) 3.59
Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem (1989) 3.51
Identification of effector residues and a neutralizing epitope of Ha-ras-encoded p21. Proc Natl Acad Sci U S A (1986) 3.11
Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J Biol Chem (1988) 3.10
Mammalian and yeast ras gene products: biological function in their heterologous systems. Science (1985) 3.03
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med (1995) 2.99
A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med (1993) 2.98
Yeast and mammalian ras proteins have conserved biochemical properties. Nature (1985) 2.85
Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc Natl Acad Sci U S A (1987) 2.81
Ligand binding to the beta-adrenergic receptor involves its rhodopsin-like core. Nature (1987) 2.73
CDC25: a component of the RAS-adenylate cyclase pathway in Saccharomyces cerevisiae. Science (1987) 2.67
Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci U S A (1991) 2.67
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol (1990) 2.65
Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (1993) 2.60
Purification of ras GTPase activating protein from bovine brain. Proc Natl Acad Sci U S A (1988) 2.41
Structural features required for ligand binding to the beta-adrenergic receptor. EMBO J (1987) 2.41
Structural basis of beta-adrenergic receptor function. FASEB J (1989) 2.27
HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem Biophys Res Commun (1988) 2.14
A C-terminal domain of GAP is sufficient to stimulate ras p21 GTPase activity. EMBO J (1989) 2.14
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis (2000) 2.10
Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother (1993) 2.10
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem (1994) 2.07
Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. J Biol Chem (1990) 1.95
Purification and properties of thiol beta-lactamase. A mutant of pBR322 beta-lactamase in which the active site serine has been replaced with cysteine. J Biol Chem (1984) 1.88
Sequence of the gene encoding the human M1 muscarinic acetylcholine receptor. Nucleic Acids Res (1987) 1.80
Thiol-beta-lactamase: replacement of the active-site serine of RTEM beta-lactamase by a cysteine residue. Proc Natl Acad Sci U S A (1982) 1.74
Identification of guanine nucleotides bound to ras-encoded proteins in growing yeast cells. J Biol Chem (1987) 1.74
Monoclonal antibody that inhibits infection of HeLa and rhabdomyosarcoma cells by selected enteroviruses through receptor blockade. J Virol (1986) 1.68
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA (1998) 1.59
Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrob Agents Chemother (1994) 1.53
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A (1994) 1.52
Regulatory function of the Saccharomyces cerevisiae RAS C-terminus. Mol Cell Biol (1987) 1.51
Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J Biol Chem (1994) 1.51
Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res (2001) 1.46
Chemical synthesis and enzymatic activity of a 99-residue peptide with a sequence proposed for the human immunodeficiency virus protease. Proc Natl Acad Sci U S A (1988) 1.36
Application of the indirect enzyme-labeled antibody microtest to the detection and surveillance of animal diseases. J Infect Dis (1977) 1.36
Mutations that uncouple the beta-adrenergic receptor from Gs and increase agonist affinity. J Biol Chem (1987) 1.36
Ras interaction with the GTPase-activating protein (GAP). Proteins (1989) 1.35
HIV and multidrug resistance. Nature (1993) 1.31
A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity. J Virol Methods (1988) 1.31
Inhibition of human immunodeficiency virus-1 reverse transcriptase activity by rubromycins: competitive interaction at the template.primer site. Mol Pharmacol (1990) 1.30
4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J Med Chem (2000) 1.30
Oxygen utilization by slime organisms in continuous culture. Air Water Pollut (1966) 1.30
Human immunodeficiency virus protease. Bacterial expression and characterization of the purified aspartic protease. J Biol Chem (1989) 1.28
Host cell factor requirement for hepatitis C virus enzyme maturation. Proc Natl Acad Sci U S A (2001) 1.27
Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol (1994) 1.26
Characterization of an active single polypeptide form of the human immunodeficiency virus type 1 protease. J Biol Chem (1990) 1.25
The herpesvirus proteases as targets for antiviral chemotherapy. Antivir Chem Chemother (2000) 1.21
Antigenic conservation and divergence between the viral-specific proteins of poliovirus type 1 and various picornaviruses. Virology (1985) 1.20
An adenylate cyclase from Saccharomyces cerevisiae that is stimulated by RAS proteins with effector mutations. Mol Cell Biol (1988) 1.19
The carboxyl terminus of the hamster beta-adrenergic receptor expressed in mouse L cells is not required for receptor sequestration. Cell (1987) 1.19
Inhibition of human immunodeficiency virus integrase by bis-catechols. Antimicrob Agents Chemother (1995) 1.15
A single amino acid substitution in the beta-adrenergic receptor promotes partial agonist activity from antagonists. J Biol Chem (1989) 1.15
Xenopus oocyte germinal-vesicle breakdown induced by [Val12]Ras is inhibited by a cytosol-localized Ras mutant. Proc Natl Acad Sci U S A (1989) 1.15
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design. J Med Chem (1992) 1.10
Role of coenzyme in aminotransferase turnover. J Biol Chem (1977) 1.06
Affinity purification of the HIV-1 protease. Biochem Biophys Res Commun (1989) 1.05
A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. J Med Chem (1995) 1.05
Structure-function analysis of the beta-adrenergic receptor. Cold Spring Harb Symp Quant Biol (1988) 1.04
Dimerization and activation of the herpes simplex virus type 1 protease. J Biol Chem (1997) 1.02
Temporal and spatial prediction of radiocaesium transfer to food products. Radiat Environ Biophys (2001) 1.00
Activity and dimerization of human immunodeficiency virus protease as a function of solvent composition and enzyme concentration. J Biol Chem (1992) 0.99
Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem (1994) 0.98
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution. J Med Chem (1980) 0.97
HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity. J Med Chem (1992) 0.96
Separation of the structural requirements for agonist-promoted activation and sequestration of the beta-adrenergic receptor. Mol Pharmacol (1990) 0.95
Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands. J Med Chem (1993) 0.93
L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro. Antimicrob Agents Chemother (1992) 0.93
Fluorescent oligonucleotides and deoxynucleotide triphosphates: preparation and their interaction with the large (Klenow) fragment of Escherichia coli DNA polymerase I. Biochemistry (1989) 0.92
Agonist-promoted sequestration of the beta 2-adrenergic receptor requires regions involved in functional coupling with Gs. Mol Pharmacol (1989) 0.92